A systematic review on the complications and management of hepatic adenomas: a call for a new approach.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
21
5
2020
medline:
29
7
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Hepatic adenomas are benign hepatic lesions with heterogeneous characteristics. Awareness of complications, including haemorrhage and malignant transformation, has improved alongside a concurrent rise in their detection. Monitoring and management guidelines, however, remain inconsistent. This systematic review analyses the natural history of hepatic adenomas, and existing and novel risk factors associated with haemorrhage and malignant transformation. Results of this systematic review commonly identified male sex, and the beta-catenin histopathological hepatic adenoma subtype, as risk factors for malignant transformation, whilst those associated with haemorrhage included lesion size and number, exophytic nature, and recent hormone use. Overall, females demonstrated higher rates of haemorrhage, whilst males exhibited a higher risk of hepatocellular carcinoma development. This systematic review highlights that tumour size and subtype may not be as characteristically linked with complications as previously thought. We have additionally reported novel risk factors contributing to development of hepatic adenoma-related complications. We conclude by highlighting the risk of taking a conservative approach to seemingly low-risk lesions and suggest revised practice guidelines.
Identifiants
pubmed: 32433418
doi: 10.1097/MEG.0000000000001766
pii: 00042737-202008000-00004
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
923-930Références
Tonorezos ES, Barnea D, Abou-Alfa GK, Bromberg J, D’Angelica M, Sklar CA, et al. Hepatocellular adenoma among adult survivors of childhood and young adult cancer. Pediatr Blood Cancer. 2017; 64
Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 2011; 26:28–35
Ponnatapura J, Kielar A, Burke LMB, Lockhart ME, Abualruz AR, Tappouni R, Lalwani N. Hepatic complications of oral contraceptive pills and estrogen on MRI: controversies and update – adenoma and beyond. Magn Reson Imaging. 2019; 60:110–121
Bagia S, Hewitt PM, Morris DL. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder. Aust N Z J Surg. 2000; 70:686–687
Bröker MEE, Gaspersz MP, Klompenhouwer AJ, Hansen BE, Terkivatan T, Taimr P, et al. Inflammatory and multiple hepatocellular adenoma are associated with a higher BMI. Eur J Gastroenterol Hepatol. 2017; 29:1183–1188
Shafizadeh N, Genrich G, Ferrell L, Kakar S. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up. Hum Pathol. 2014; 45:976–983
van Aalten SM, Verheij J, Terkivatan T, Dwarkasing RS, de Man RA, Ijzermans JN. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol. 2011; 55:120–125
Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J. Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol. 2017; 67:1074–1083
Thomeer MG, E Bröker ME, de Lussanet Q, Biermann K, Dwarkasing RS, de Man R, et al. Genotype-phenotype correlations in hepatocellular adenoma: an update of MRI findings. Diagn Interv Radiol. 2014; 20:193–199
Thomeer MG, Willemssen FE, Biermann KK, El Addouli H, de Man RA, Ijzermans JN, Dwarkasing RS. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents. J Magn Reson Imaging. 2014; 39:1259–1264
Ba-Ssalamah A, Antunes C, Feier D, Bastati N, Hodge JC, Stift J, et al. Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Radiology. 2015; 277:104–113
Battula N, Tsapralis D, Takhar A, Coldham C, Mayer D, Isaac J, et al. Aetio-pathogenesis and the management of spontaneous liver bleeding in the west: a 16-year single-centre experience. HPB (Oxford). 2012; 14:382–389
Maoz D, Sharon E, Chen Y, Grief F. Spontaneous hepatic rupture: 13-year experience of a single center. Eur J Gastroenterol Hepatol. 2010; 22:997–1000
Mandrekar JN, Mandrekar SJ. Systematic reviews and meta-analysis of published studies: an overview and best practices. J Thorac Oncol. 2011; 6:1301–1303
Bise S, Frulio N, Hocquelet A, Alberti N, Blanc JF, Laurent C, et al. New MRI features improve subtype classification of hepatocellular adenoma. Eur Radiol. 2019; 29:2436–2447
Huang WC, Liau JY, Jeng YM, Liu KL, Lin CN, Song HL, et al. Hepatocellular adenoma in Taiwan: distinct ensemble of male predominance, overweight/obesity, and inflammatory subtype. J Gastroenterolhepatol. 2019; 35:680–688
Putra J, Ferrell LD, Gouw ASH, Paradis V, Rishi A, Sempoux C, et al. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon. Mod Pathol. 2020; 33:665–675
Shao N, Pandey A, Ghasabeh MA, Khoshpouri P, Pandey P, Varzaneh FN, et al. Long-term follow-up of hepatic adenoma and adenomatosis: analysis of size change on imaging with histopathological correlation. Clin Radiol. 2018; 73:958–965
Bossen L, Grønbaek H, Lykke Eriksen P, Jepsen P. Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: a nationwide population-based study. Liver Int. 2017; 37:1042–1046
Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017; 152:880–94 e6
Kwok WY, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, et al. Malignant transformation of hepatocellular adenoma. Oncology. 2017; 92Suppl 116–28
Sinclair M, Schelleman A, Sandhu D, Angus PW. Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy. Hepatology. 2017; 66:989–991
Klompenhouwer AJ, Sprengers D, Willemssen FE, Gaspersz MP, Ijzermans JN, De Man RA. Evidence of good prognosis of hepatocellular adenoma in post-menopausal women. J Hepatol. 2016; 65:1163–1170
Laurent A, Dokmak S, Nault JC, Pruvot FR, Fabre JM, Letoublon C, et al.; AFC-HCA-2013 Study Group. European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group. HPB (Oxford). 2016; 18:748–755
Tse JR, Naini BV, Lu DS, Raman SS. Qualitative and quantitative gadoxetic acid-enhanced MR imaging helps subtype hepatocellular adenomas. Radiology. 2016; 279:118–127
Chun YS, Parker RJ, Inampudi S, Ehrenwald E, Batts KP, Burgart LJ, et al. Imaging surveillance of hypervascular liver lesions in non-cirrhotic patients. J Gastrointest Surg. 2016; 20:564–567
Mounajjed T, Yasir S, Aleff PA, Torbenson MS. Pigmented hepatocellular adenomas have a high risk of atypia and malignancy. Mod Pathol. 2015; 28:1265–1274
Stueck AE, Qu Z, Huang MA, Campreciós G, Ferrell LD, Thung SN. Hepatocellular carcinoma arising in an HNF-1α-mutated adenoma in a 23-Year-old woman with maturity-onset diabetes of the young: a case report. Semin Liver Dis. 2015; 35:444–449
An SL, Wang LM, Rong WQ, Wu F, Sun W, Yu WB, et al. Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers. Chin J Cancer. 2015; 34:217–224
Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol. 2014; 27:420–432
Tokoro T, Kato Y, Sugioka A, Mizoguchi Y. Malignant transformation of hepatocellular adenoma over a decade. BMJ Case Rep. 2014; 2014:bcr2014205261
Bieze M, Phoa SS, Verheij J, van Lienden KP, van Gulik TM. Risk factors for bleeding in hepatocellular adenoma. Br J Surg. 2014; 101:847–855
Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut. 2011; 60:85–89
Bunchorntavakul C, Bahirwani R, Drazek D, Soulen MC, Siegelman ES, Furth EE, et al. Clinical features and natural history of hepatocellular adenomas: the impact of obesity. Aliment Pharmacol Ther. 2011; 34:664–674
Deneve JL, Pawlik TM, Cunningham S, Clary B, Reddy S, Scoggins CR, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol. 2009; 16:640–648
Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the bordeaux experience. Hepatology. 2009; 50:481–489
Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009; 137:1698–1705
Cho SW, Marsh JW, Steel J, Holloway SE, Heckman JT, Ochoa ER, et al. Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol. 2008; 15:2795–2803
Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol. 2008; 21:491–497
Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006; 43:515–524
Mohajer K, Frydrychowicz A, Robbins JB, Loeffler AG, Reed TD, Reeder SB. Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging. 2012; 36:686–696
Abir A, Cazejust J, Arrivé L, Menu Y. MR features of inflammatory hepatic adenoma. Clin Res Hepatol Gastroenterol. 2013; 37:109–110
Denecke T, Steffen IG, Agarwal S, Seehofer D, Kröncke T, Hänninen EL, et al. Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI. Eur Radiol. 2012; 22:1769–1775
Yoneda N, Matsui O, Kitao A, Kozaka K, Gabata T, Sasaki M, et al. Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol. 2012; 30:777–782
Dharmana H, Saravana-Bawan S, Girgis S, Low G. Hepatocellular adenoma: imaging review of the various molecular subtypes. Clin Radiol. 2017; 72:276–285
Wang H, Yang C, Rao S, Ji Y, Han J, Sheng R, Zeng M. MR imaging of hepatocellular adenomas on genotype-phenotype classification: a report from China. Eur J Radiol. 2018; 100:135–141
Ronot M, Bahrami S, Calderaro J, Valla DC, Bedossa P, Belghiti J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology. 2011; 53:1182–1191
Zhang C, Shi X, Zhao L. Synchronous giant hepatic adenoma in siblings-a case report and brief literature review. Cancer Biol Ther. 2016; 17:727–731
Klompenhouwer AJ, Bröker MEE, Thomeer MGJ, Gaspersz MP, de Man RA, IJzermans JNM. Retrospective study on timing of resection of hepatocellular adenoma. Br J Surg. 2017; 104:1695–1703
Agrawal S, Agarwal S, Arnason T, Saini S, Belghiti J. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol Hepatol. 2015; 13:1221–1230
Dokmak S, Aussilhou B, Rasoaherinomenjanahary F, Ronot M, Dahdouh R, Ftériche FS, et al. Hemorrhage of hepatocellular adenoma: a complication that can be treated by conservative management without surgery. HPB (Oxford). 2018; 20:1198–1205
van Rosmalen BV, Coelen RJS, Bieze M, van Delden OM, Verheij J, Dejong CHC, van Gulik TM. Systematic review of transarterial embolization for hepatocellular adenomas. Br J Surg. 2017; 104:823–835
Smolock AR, Cristescu MM, Potretzke TA, Ziemlewicz TJ, Lubner MG, Hinshaw JL, et al. Microwave ablation for the treatment of hepatic adenomas. J Vasc Interv Radiol. 2016; 27:244–249
Karkar AM, Tang LH, Kashikar ND, Gonen M, Solomon SB, Dematteo RP, et al. Management of hepatocellular adenoma: comparison of resection, embolization and observation. HPB (Oxford). 2013; 15:235–243
Blaise L, Sutter O, Ziol M, Nault JC. Benign liver tumors. Rev Prat. 2018; 68:1119–1124
Dokmak S, Belghiti J. Will weight loss become a future treatment of hepatocellular adenoma in obese patients? Liver Int. 2015; 35:2228–2232
Gevers TJG, Marcel Spanier BW, Veendrick PB, Vrolijk JM. Regression of hepatocellular adenoma after bariatric surgery in severe obese patients. Liver Int. 2018; 38:2134–2136
Yamaguchi T, Kokudo T, Zingg T, Halkic N. The management of hepatocellular adenoma in obese patients: issues to consider. Liver Int. 2016; 36:152
Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010; 12:509–522
Terkivatan T, Ijzermans JN. Hepatocellular adenoma: should phenotypic classification direct management? Nat Rev Gastroenterol Hepatol. 2009; 6:697–698
van Aalten SM, de Man RA, IJzermans JN, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg. 2012; 99:911–916
van Vledder MG, van Aalten SM, Terkivatan T, de Man RA, Leertouwer T, Ijzermans JN. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol. 2011; 22:787–793
Maroulis I, Spyropoulos C, Kalogeropoulou C, Karavias D. Use of radiofrequency ablation for controlling liver hemorrhage in the emergency setting; report of two cases and review of the literature. Ulus Travma Acil Cerrahi Derg. 2013; 19:167–172
Silva JP, Klooster B, Tsai S, Christians KK, Clarke CN, Mogal H, Clark Gamblin T. elective regional therapy treatment for hepatic adenoma. Ann Surg Oncol. 2019; 26:125–130
Mironov O, Jaberi A, Beecroft R, Kachura JR. Retrospective single-arm cohort study of patients with hepatocellular adenomas treated with percutaneous thermal ablation. Cardiovasc Intervent Radiol. 2018; 41:935–941